JP2019504024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504024A5 JP2019504024A5 JP2018532419A JP2018532419A JP2019504024A5 JP 2019504024 A5 JP2019504024 A5 JP 2019504024A5 JP 2018532419 A JP2018532419 A JP 2018532419A JP 2018532419 A JP2018532419 A JP 2018532419A JP 2019504024 A5 JP2019504024 A5 JP 2019504024A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- component
- reducing agent
- group
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 9
- -1 alkali metal salts Chemical class 0.000 claims 4
- 239000003638 chemical reducing agent Substances 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000001508 potassium citrate Substances 0.000 claims 2
- 229960002635 potassium citrate Drugs 0.000 claims 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims 2
- 235000011082 potassium citrates Nutrition 0.000 claims 2
- 229960004402 tiopronin Drugs 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 206010007027 Calculus urinary Diseases 0.000 claims 1
- 206010011778 Cystinuria Diseases 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 208000000913 Kidney Calculi Diseases 0.000 claims 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- 206010029148 Nephrolithiasis Diseases 0.000 claims 1
- 108010058907 Tiopronin Proteins 0.000 claims 1
- 208000006568 Urinary Bladder Calculi Diseases 0.000 claims 1
- 208000009911 Urinary Calculi Diseases 0.000 claims 1
- 230000003113 alkalizing effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960003067 cystine Drugs 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 239000004337 magnesium citrate Substances 0.000 claims 1
- 229960005336 magnesium citrate Drugs 0.000 claims 1
- 235000002538 magnesium citrate Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910000030 sodium bicarbonate Chemical class 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 229960001790 sodium citrate Drugs 0.000 claims 1
- 235000011083 sodium citrates Nutrition 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000034005 thiol-disulfide exchange Effects 0.000 claims 1
- 150000003573 thiols Chemical group 0.000 claims 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271020P | 2015-12-22 | 2015-12-22 | |
| US62/271,020 | 2015-12-22 | ||
| US201562272894P | 2015-12-30 | 2015-12-30 | |
| US62/272,894 | 2015-12-30 | ||
| PCT/US2016/067466 WO2017112574A1 (en) | 2015-12-22 | 2016-12-19 | Pharmaceutical formulations for treating kidney stones and methods for fabricating and using thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019504024A JP2019504024A (ja) | 2019-02-14 |
| JP2019504024A5 true JP2019504024A5 (enExample) | 2020-02-06 |
Family
ID=59064032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532419A Pending JP2019504024A (ja) | 2015-12-22 | 2016-12-19 | 腎結石を治療する医薬製剤ならびにその製造方法および用法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20170172960A1 (enExample) |
| EP (1) | EP3393469A4 (enExample) |
| JP (1) | JP2019504024A (enExample) |
| KR (1) | KR20180095647A (enExample) |
| AU (1) | AU2016378399A1 (enExample) |
| CA (1) | CA3009332A1 (enExample) |
| WO (1) | WO2017112574A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018285927B2 (en) * | 2017-06-16 | 2023-04-20 | Altibio, Inc. | Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders |
| US20190282525A1 (en) * | 2018-03-19 | 2019-09-19 | Cronus Research Labs Private Limited | Tiopronin oral composition |
| WO2020092402A1 (en) * | 2018-10-30 | 2020-05-07 | Harrow Health, Inc. | Pharmaceutical compositions of tiopronin and methods for preparing thereof |
| US20220016078A1 (en) * | 2020-07-14 | 2022-01-20 | GyanRx Sciences, Inc. | Methods Of Treating Kidney Stones |
| US20240254098A1 (en) * | 2021-05-10 | 2024-08-01 | Altibio, Inc. | Thioester prodrugs for the treatment of renal anomalies |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050025839A1 (en) * | 2003-07-28 | 2005-02-03 | Polli James Edward | Formulation approach to enhance transporter-mediated drug uptake |
| CN100361653C (zh) * | 2004-09-29 | 2008-01-16 | 上海华源医药科技发展有限公司 | 硫普罗宁软胶囊 |
| AR052225A1 (es) * | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones |
| CN1833637A (zh) * | 2005-03-16 | 2006-09-20 | 安徽龙科马生物制药有限责任公司 | 一种新的硫普罗宁冻干粉制剂及其制备方法 |
| CN1698594A (zh) * | 2005-04-25 | 2005-11-23 | 中国药科大学 | 硫普罗宁的缓释制剂 |
| CN101062024B (zh) * | 2006-04-25 | 2012-11-07 | 刘祥华 | 一种硫普罗宁组合药物及其制备方法 |
| FR2967578B1 (fr) * | 2010-11-18 | 2012-12-28 | Advicenne Pharma | Composition pharmaceutique comportant des sels de citrate et de bicarbonate, et son utilisation pour le traitement de la cystinurie |
| US8916609B2 (en) * | 2011-06-10 | 2014-12-23 | New York University | Compounds as L-cystine crystallization inhibitors and uses thereof |
| CN102516143B (zh) * | 2012-01-06 | 2013-11-20 | 刘全胜 | 一种硫普罗宁无菌粉及其制剂与制备方法 |
| WO2014145195A1 (en) * | 2013-03-15 | 2014-09-18 | Cerovene, Inc. | Pharmaceuticals comprising a ph-dependent component and ph-raising agent |
-
2016
- 2016-12-19 JP JP2018532419A patent/JP2019504024A/ja active Pending
- 2016-12-19 EP EP16879926.0A patent/EP3393469A4/en not_active Withdrawn
- 2016-12-19 US US15/383,211 patent/US20170172960A1/en not_active Abandoned
- 2016-12-19 CA CA3009332A patent/CA3009332A1/en not_active Abandoned
- 2016-12-19 WO PCT/US2016/067466 patent/WO2017112574A1/en not_active Ceased
- 2016-12-19 KR KR1020187020408A patent/KR20180095647A/ko not_active Withdrawn
- 2016-12-19 AU AU2016378399A patent/AU2016378399A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019504024A5 (enExample) | ||
| HRP20240564T1 (hr) | Novi farmaceutski sastav | |
| JP2015038135A5 (enExample) | ||
| JP2006516570A5 (enExample) | ||
| JP2013231087A5 (enExample) | ||
| JP2012255026A5 (enExample) | ||
| FI3782612T3 (fi) | Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| BRPI0414311A (pt) | formas de dosagem de liberação controlada | |
| JP2009541348A5 (enExample) | ||
| JP2005507400A5 (enExample) | ||
| HRP20211862T1 (hr) | Pripravci za i postupci liječenja anemije | |
| HRP20231613T1 (hr) | Pripravci koji sadrže sredstvo za unošenje i njihova priprava | |
| RU2014115287A (ru) | Фармацевтическая композиция для перорального введения с маскированным вкусом и способ ее получения | |
| HRP20230616T1 (hr) | Disperzivni pripravci | |
| JP2015511609A5 (enExample) | ||
| JP2008543936A5 (enExample) | ||
| JP2005528430A5 (enExample) | ||
| JP2007523210A5 (enExample) | ||
| JP2008519070A5 (enExample) | ||
| NZ611026A (en) | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | |
| RU2016117186A (ru) | Комбинированная композиция, содержащая тадалафил и амлодипин | |
| JP2020533296A5 (enExample) | ||
| IL174830A0 (en) | Pellets containing venlafaxine hydrochloride, pharmaceutical compositions comprising them and processes for their preparation |